Related Experiment Video
Updated: Jun 30, 2025
06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
35.2K
A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer.
Takuma Uo1, Kayode K Ojo2, Cynthia C T Sprenger1
1Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, Washington.
Molecular Cancer Therapeutics
|March 20, 2024
Summary
A new drug candidate, BKIDC-1553, shows promise in inhibiting prostate cancer growth by targeting glycolysis. This novel antiglycolytic agent demonstrates preclinical efficacy and safety, supporting its advancement into clinical trials for advanced prostate cancer.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) is an incurable malignancy.
- Prostate tumors exhibit increased glycolysis, a metabolic vulnerability.
- Previous non-specific glycolysis inhibitors caused systemic toxicity, limiting their use.
Purpose of the Study:
- To evaluate the preclinical activity, safety, and pharmacokinetics of BKIDC-1553, a novel antiglycolytic small-molecule inhibitor.
- To investigate the mechanism of action and therapeutic potential of BKIDC-1553 in prostate cancer models.
Main Methods:
- In vitro proliferation assays across prostate cancer cell lines.
- Cell-cycle, metabolic, and enzymatic assays to determine mechanism of action.
- In vivo studies using patient-derived xenografts and human organoids.
- Pharmacokinetic (ADME) and toxicology assessments.
Main Results:
- BKIDC-1553 selectively inhibits hexokinase 2, a key glycolytic enzyme, in prostate cancer cells.
- Demonstrated selective growth inhibition across multiple prostate cancer models.
- Showed promising efficacy in a preclinical xenograft model, comparable to enzalutamide.
- Exhibited favorable safety and pharmacokinetic profiles suitable for clinical development.
Conclusions:
- BKIDC-1553 represents a new class of small-molecule antiglycolytic agents targeting hexokinase 2.
- The compound displays significant preclinical activity and a favorable safety margin.
- BKIDC-1553 warrants further clinical investigation for advanced prostate cancer treatment.
Related Concept Videos
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:53Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K